Literature DB >> 33579806

Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates.

Olivier Barret1,2, Lei Zhang3, David Alagille4,5, Cristian C Constantinescu4, Christine Sandiego4, Caroline Papin4, Jenna M Sullivan4, Thomas Morley4, Vincent M Carroll4, John Seibyl4, Jianqing Chen6, Chewah Lee3, Anabella Villalobos3, David Gray3,7, Timothy J McCarthy6, Gilles Tamagnan4,5.   

Abstract

Non-catechol-based high-affinity selective dopamine D1 receptor (D1R) agonists were recently described, and candidate PET ligands were selected on the basis of favorable properties. The objective of this study was to characterize in vivo in nonhuman primates 2 novel D1R agonist PET radiotracers, racemic 18F-MNI-800 and its more active atropisomeric (-)-enantiomer, 18F-MNI-968.
Methods: Ten brain PET experiments were conducted with 18F-MNI-800 on 2 adult rhesus macaques and 2 adult cynomolgus macaques, and 8 brain PET experiments were conducted with 18F-MNI-968 on 2 adult rhesus macaques and 2 adult cynomolgus macaques. PET data were analyzed with both plasma-input-based methods and reference-region-based methods. Whole-body PET images were acquired with 18F-MNI-800 from 2 adult rhesus macaques for radiation dosimetry estimates.
Results: 18F-MNI-800 and 18F-MNI-968 exhibited regional uptake consistent with D1R distribution. Specificity and selectivity were demonstrated by dose-dependent blocking with the D1 antagonist SCH-23390. 18F-MNI-968 showed a 30% higher specific signal than 18F-MNI-800, with a nondisplaceable binding potential of approximately 0.3 in the cortex and approximately 1.1 in the striatum. Dosimetry radiation exposure was favorable, with an effective dose of about 0.023 mSv/MBq.
Conclusion: 18F-MNI-968 has significant potential as a D1R agonist PET radiotracer, and further characterization in human subjects is warranted.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  D1 receptor; PET imaging; Parkinson disease; agonist; schizophrenia

Mesh:

Substances:

Year:  2021        PMID: 33579806      PMCID: PMC8882897          DOI: 10.2967/jnumed.120.256008

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

Review 1.  Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers.

Authors:  M Slifstein; M Laruelle
Journal:  Nucl Med Biol       Date:  2001-07       Impact factor: 2.408

2.  Measurement of cortical dopamine d1 receptor binding with 11C[SCH23390]: a test-retest analysis.

Authors:  J Hirvonen; K Någren; J Kajander; J Hietala
Journal:  J Cereb Blood Flow Metab       Date:  2001-10       Impact factor: 6.200

3.  Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited.

Authors:  Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-09       Impact factor: 6.200

4.  Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain.

Authors:  H Hall; G Sedvall; O Magnusson; J Kopp; C Halldin; L Farde
Journal:  Neuropsychopharmacology       Date:  1994-12       Impact factor: 7.853

5.  Dopamine receptor mRNA expression in human striatum and neocortex.

Authors:  J H Meador-Woodruff; S P Damask; J Wang; V Haroutunian; K L Davis; S J Watson
Journal:  Neuropsychopharmacology       Date:  1996-07       Impact factor: 7.853

Review 6.  Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation.

Authors:  Adrian Hall; Laurent Provins; Anne Valade
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

7.  Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys.

Authors:  J S Schneider; Z Q Sun; D P Roeltgen
Journal:  Brain Res       Date:  1994-11-07       Impact factor: 3.252

8.  [11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors.

Authors:  M Kassiou; U Scheffel; H T Ravert; W B Mathews; J L Musachio; R M Lambrecht; R F Dannals
Journal:  Nucl Med Biol       Date:  1995-02       Impact factor: 2.408

9.  Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.

Authors:  Daniel R Rosell; Lauren C Zaluda; Margaret M McClure; M Mercedes Perez-Rodriguez; K Sloan Strike; Deanna M Barch; Philip D Harvey; Ragy R Girgis; Erin A Hazlett; Richard B Mailman; Anissa Abi-Dargham; Jeffrey A Lieberman; Larry J Siever
Journal:  Neuropsychopharmacology       Date:  2014-07-30       Impact factor: 7.853

10.  In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390.

Authors:  Jesper Ekelund; Mark Slifstein; Raj Narendran; Olivier Guillin; Hemant Belani; Ning-Ning Guo; Yuying Hwang; Dah-Ren Hwang; Anissa Abi-Dargham; Marc Laruelle
Journal:  Mol Imaging Biol       Date:  2007 May-Jun       Impact factor: 3.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.